Hier nog het advies waaraan Dieter refereert, in zijn tweet:
Affimed NV (NASDAQ: AFMD)
Affimed is by no means a Vertex Pharmaceuticals in terms of scale, but, in my view, the potential growth of this company could mirror or exceed that of Vertex.
Affimed is a clinical-stage biotechnology company that’s focused on the treatment of cancer. However, the company’s method of treatment is unlike anything on the market today. Today’s cancer treatments involve targeting and essentially poisoning cancer cells to kill them, stop their reproduction, and ultimately cure, or extend the life of the patient.
Unfortunately, these drugs damage the human body, with systemic reactions often, making the treatment period a relatively miserable experience and setting the stage for significant adverse events, up to and including death.
Affimed wants to change this. Instead of sending harsh chemicals into the human body, the company is working to tap into the largely untapped potential of the human body’s innate immune system.
The company’s flagship candidate is known as ROCK is a pipeline of innate cell engagers designed to essentially wake up the cells within the innate immune system and target those cells to specific types of hematologic and solid tumor types.
The method of treatment is promising too, with early clinical data surrounding AFM13 resulting in a significant disease reduction in all patients who have received the treatment to date. Moreover, there were no signs of cytokine release or neurotoxicity, giving the treatment a much more favorable safety profile than most treatments on the market today.
With a long pipeline of candidates that are showing promise in the treatment of some of the world’s most difficult-to-treat types of cancer, AFMD is a stock to pay close attention to.